Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647516 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
- 20
- Study locations
NCT01647516 is a Phase 2 study of Ulcerative Colitis that has completed, run by Celgene. The registered enrollment target is 199 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT01647516, a Phase 2 study of Ulcerative Colitis, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ozanimod
Study Locations (20)
Other
- Universitair Ziekenhuis Leuven, Campus Gasthuisberg - Leuven
- Multiprofile Hospital for Active Treatment Kaspela - Plovdiv
- University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia - Sofia
- UMHAT Sv Ivan Rilski EAD - Sofia
- University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD - Sofia
- Military Medical Academy - Sofia
- Multiprofile Hospital for Active Treatment Doverie AD - Sofia
- Multiprofile Hospital for Active Treatment Sveti Panteleimon - Sofia AD - Sofia
- Multiprofile Hospital for Active Treatment Sofiamed - Sofia
California
- Anaheim Clinical Trials - Anaheim
- University of California San Diego - La Jolla
- Alliance Clinical Research - Oceanside
Maryland
- Chevy Chase Clinical Research - Chevy Chase
- Endoscopic Microsurgery Associates - Towson
Georgia
- Atlanta Gastroenterology Associates, LLC - Atlanta
Michigan
- Clinical Research Institute of Michigan, LLC - Chesterfield
New York
- Long Island Clinical Research Associates - Great Neck
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Consultants for Clinical Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2012-12-26 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647516
The ClinicalTrials.gov registry entry for NCT01647516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (90% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01647516 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT01647516 about?
NCT01647516 is a clinical study titled "Efficacy and Safety Study of Ozanimod in Ulcerative Colitis". The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
What is the current status of trial NCT01647516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2012-12-26. Estimated completion is 2019-08-30.
What conditions does trial NCT01647516 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01647516?
The interventions under investigation include: Placebo (DRUG), Ozanimod (DRUG).
Who is sponsoring clinical trial NCT01647516?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01647516 being conducted?
This trial has 20 study locations across California, Georgia, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.